BR0313397A - Inibidores de proteina cinase e usos destes - Google Patents
Inibidores de proteina cinase e usos destesInfo
- Publication number
- BR0313397A BR0313397A BR0313397-4A BR0313397A BR0313397A BR 0313397 A BR0313397 A BR 0313397A BR 0313397 A BR0313397 A BR 0313397A BR 0313397 A BR0313397 A BR 0313397A
- Authority
- BR
- Brazil
- Prior art keywords
- protein kinase
- kinase inhibitors
- disorders
- compounds
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
"INIBIDORES DE PROTEìNA CINASE E USOS DESTES". A presente invenção refere-se a compostos que são úteis como inibidores de proteína cinase tendo as fórmulas (I) e (V) ou um sal farmaceuticamente aceitável destes, em que o Anel B, Z^ 1^, Z^ 2^ U, T, m, n, p, Q, Q<39>, R^ 1^, R^ 2^, R^ x^, R^ 3^ e R^ 6^ são como definido aqui. Estes compostos, e composições farmaceuticamente aceitáveis destes, são úteis para tratar ou reduzir a gravidade de uma variedade de distúrbios, incluindo acidente vascular cerebral, distúrbios inflamatórios, doenças auto-imunes, tais como, lúpus SLE e psoríase, distúrbios proliferativos, tais como, câncer, e condições associadas com transplante de órgão.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40325602P | 2002-08-14 | 2002-08-14 | |
US41680202P | 2002-10-08 | 2002-10-08 | |
PCT/US2003/025333 WO2004016597A2 (en) | 2002-08-14 | 2003-08-12 | Protein kinase inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313397A true BR0313397A (pt) | 2005-06-28 |
Family
ID=31891378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313397-4A BR0313397A (pt) | 2002-08-14 | 2003-08-12 | Inibidores de proteina cinase e usos destes |
Country Status (15)
Country | Link |
---|---|
US (1) | US7304071B2 (pt) |
EP (1) | EP1546117A2 (pt) |
JP (1) | JP4741948B2 (pt) |
KR (1) | KR20050042478A (pt) |
AR (1) | AR040870A1 (pt) |
AU (1) | AU2003262642B2 (pt) |
BR (1) | BR0313397A (pt) |
CA (1) | CA2495386C (pt) |
MX (1) | MXPA05001804A (pt) |
NO (1) | NO20051207L (pt) |
NZ (1) | NZ538715A (pt) |
PL (1) | PL375447A1 (pt) |
RU (1) | RU2005106871A (pt) |
TW (1) | TW200406388A (pt) |
WO (1) | WO2004016597A2 (pt) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001040800A2 (en) * | 1999-11-30 | 2001-06-07 | Parker Hughes Institute | Syk localized at centrosome |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US20040171062A1 (en) * | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
ATE451104T1 (de) | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
WO2004024895A2 (en) * | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
JP4808154B2 (ja) * | 2003-03-13 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用な組成物 |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
EP1644365A2 (en) * | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
AU2004261484A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
CN1849318B (zh) * | 2003-07-30 | 2011-10-12 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法 |
WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1809614B1 (en) * | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
EP1751133B1 (en) * | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
EP1753738B1 (en) * | 2004-05-14 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds |
US7550598B2 (en) * | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
PL382308A1 (pl) | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
WO2006034207A2 (en) * | 2004-09-17 | 2006-03-30 | Vanderbilt University | Use of gsk3 inhibitors in combination with radiation therapies |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
WO2006093247A1 (ja) | 2005-02-28 | 2006-09-08 | Japan Tobacco Inc. | Syk阻害活性を有する新規なアミノピリジン化合物 |
JP2008543775A (ja) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
KR101312225B1 (ko) | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Jak 경로의 억제를 위한 조성물 및 방법 |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
ES2279500T3 (es) * | 2005-06-17 | 2007-08-16 | Magneti Marelli Powertrain S.P.A. | Inyector de carburante. |
JP2009501721A (ja) * | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
US8211919B2 (en) * | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
US7512864B2 (en) * | 2005-09-30 | 2009-03-31 | Josef Zeevi | System and method of accessing non-volatile computer memory |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CN101340909B (zh) | 2005-10-18 | 2012-01-11 | 詹森药业有限公司 | 抑制flt3激酶的方法 |
BR122021011787B1 (pt) * | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20070149508A1 (en) * | 2005-11-02 | 2007-06-28 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
BRPI0706747A2 (pt) * | 2006-01-30 | 2011-04-05 | Exelixis Inc | 4-aril-2-amino-pirimidinas ou 4-aril-2-aminoalquil-pirimidinas como moduladores jak-2 e composições farmacêuticas que os contenham |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
US7834178B2 (en) * | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
ATE517126T1 (de) | 2006-03-20 | 2011-08-15 | Seikagaku Kogyo Co Ltd | Therapeutikum für rheumatoide arthritis |
NZ571835A (en) | 2006-03-29 | 2011-11-25 | Velacor Therapeutics Pty Ltd | Treatment of neurodegenerative diseases |
PE20080074A1 (es) | 2006-04-20 | 2008-02-11 | Janssen Pharmaceutica Nv | Derivados de amida como agentes inhibidores de la quinasa c-fms |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
DK2021335T3 (da) | 2006-04-20 | 2011-09-05 | Janssen Pharmaceutica Nv | Heterocykliske forbindelser som C-FMS-kinasehæmmere |
CA2656564C (en) | 2006-06-29 | 2015-06-16 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
WO2008065155A1 (en) * | 2006-11-30 | 2008-06-05 | Ingenium Pharmaceuticals Gmbh | Cdk inhibitors for treating pain |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
US8445686B2 (en) | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
PL2265607T3 (pl) | 2008-02-15 | 2017-07-31 | Rigel Pharmaceuticals, Inc. | Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK |
WO2009117387A2 (en) * | 2008-03-17 | 2009-09-24 | The Trustees Of Columbia University In The City Of New York | Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
CA2723185A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CN102099491A (zh) | 2008-05-15 | 2011-06-15 | 北卡罗来纳-查佩尔山大学 | 调节血管生成的新靶标 |
US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
PT2432767E (pt) * | 2009-05-19 | 2013-07-25 | Dow Agrosciences Llc | Compostos e métodos para controlo de fungos |
SI2516434T1 (sl) | 2009-12-23 | 2015-10-30 | Takeda Pharmaceutical Company Limited | Zliti heteroaromatski pirolidinoni kot inhibitorji SYK |
US9109227B2 (en) | 2010-01-05 | 2015-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FLT3 receptor antagonists for the treatment or the prevention of pain disorders |
WO2011086085A1 (en) | 2010-01-12 | 2011-07-21 | Ab Science | Thiazole and oxazole kinase inhibitors |
US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
WO2012050921A2 (en) * | 2010-09-28 | 2012-04-19 | Nono, Inc. | Nd2 peptides and methods of treating neurological disease |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
JP6026525B2 (ja) | 2011-06-22 | 2016-11-16 | 武田薬品工業株式会社 | 置換6−アザ−イソインドリン−1−オン誘導体 |
DE102011112978A1 (de) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
IN2015DN00659A (pt) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
CN102827085A (zh) * | 2012-09-17 | 2012-12-19 | 符爱清 | 2,4,5-三氯嘧啶化合物的制备方法 |
JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. | 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法 |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
HUE041544T2 (hu) | 2013-03-12 | 2019-05-28 | Vertex Pharma | DNS-PK inhibitorok |
DK3057953T3 (en) | 2013-10-17 | 2018-11-19 | Vertex Pharma | CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS |
US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
CU24425B1 (es) * | 2013-11-01 | 2019-06-04 | Novartis Ag | Amino-heteroaril-benzamidas como inhibidores de cinasa |
JP6879740B2 (ja) * | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
AU2014361800B2 (en) | 2013-12-13 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
TW202134236A (zh) | 2014-06-12 | 2021-09-16 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
WO2016016370A1 (en) | 2014-07-31 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists |
WO2016065138A1 (en) | 2014-10-22 | 2016-04-28 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
DK3255042T3 (da) * | 2015-02-04 | 2021-02-08 | Beyondbio Inc | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme |
PL3319959T3 (pl) | 2015-07-06 | 2022-02-14 | Alkermes, Inc. | Hetero-haloinhibitory deacetylazy histonowej |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
CN108778276A (zh) | 2016-11-02 | 2018-11-09 | 安罗格制药有限责任公司 | 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
JP6756925B2 (ja) | 2017-01-11 | 2020-09-16 | ロダン・セラピューティクス,インコーポレーテッド | ヒストンデアセチラーゼの二環式阻害剤 |
US20200171022A1 (en) | 2017-05-17 | 2020-06-04 | Inserm (Institut National De La Santé Et Da La Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス,インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
CN110833551B (zh) * | 2018-08-15 | 2023-03-24 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗急性胰腺炎的用途 |
CA3117200A1 (en) | 2018-10-22 | 2020-04-30 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
US20220000868A1 (en) * | 2018-11-26 | 2022-01-06 | Gachon University Of Industry-Academic Cooperation Foundation | Novel 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof |
JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びwnt作動薬 |
WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
CN115677595A (zh) * | 2022-10-26 | 2023-02-03 | 江苏睿实生物科技有限公司 | 一种2,4,5-三氯嘧啶的制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT672041E (pt) | 1993-10-01 | 2002-04-29 | Novartis Ag | Derivados da piridina farmacologicamente activos e processos para a sua preparacao |
US5612340A (en) * | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
ATE325113T1 (de) * | 1993-10-01 | 2006-06-15 | Novartis Pharma Gmbh | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6489344B1 (en) * | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB0014022D0 (en) * | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
WO2002014281A1 (en) * | 2000-08-11 | 2002-02-21 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
AU2001295026B2 (en) * | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
ATE294797T1 (de) | 2000-09-15 | 2005-05-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
GB0107901D0 (en) | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
US7312227B2 (en) * | 2002-11-01 | 2007-12-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
EP1560824A1 (en) * | 2002-11-05 | 2005-08-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
US20070032453A1 (en) | 2005-08-04 | 2007-02-08 | Oklahoma Medical Research Foundation | Adjuvant chemotherapy for anaplastic gliomas |
-
2003
- 2003-08-12 BR BR0313397-4A patent/BR0313397A/pt not_active IP Right Cessation
- 2003-08-12 WO PCT/US2003/025333 patent/WO2004016597A2/en active Application Filing
- 2003-08-12 RU RU2005106871/04A patent/RU2005106871A/ru not_active Application Discontinuation
- 2003-08-12 NZ NZ538715A patent/NZ538715A/en not_active IP Right Cessation
- 2003-08-12 JP JP2005502048A patent/JP4741948B2/ja not_active Expired - Fee Related
- 2003-08-12 US US10/639,784 patent/US7304071B2/en not_active Expired - Fee Related
- 2003-08-12 MX MXPA05001804A patent/MXPA05001804A/es not_active Application Discontinuation
- 2003-08-12 PL PL03375447A patent/PL375447A1/xx unknown
- 2003-08-12 AU AU2003262642A patent/AU2003262642B2/en not_active Ceased
- 2003-08-12 EP EP03788433A patent/EP1546117A2/en not_active Withdrawn
- 2003-08-12 CA CA2495386A patent/CA2495386C/en not_active Expired - Fee Related
- 2003-08-12 KR KR1020057002530A patent/KR20050042478A/ko not_active Application Discontinuation
- 2003-08-13 AR AR20030102932A patent/AR040870A1/es not_active Application Discontinuation
- 2003-08-14 TW TW092122376A patent/TW200406388A/zh unknown
-
2005
- 2005-03-08 NO NO20051207A patent/NO20051207L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR040870A1 (es) | 2005-04-20 |
EP1546117A2 (en) | 2005-06-29 |
RU2005106871A (ru) | 2005-10-10 |
CA2495386A1 (en) | 2004-02-26 |
US20040106615A1 (en) | 2004-06-03 |
TW200406388A (en) | 2004-05-01 |
JP2006506462A (ja) | 2006-02-23 |
CA2495386C (en) | 2011-06-21 |
WO2004016597A3 (en) | 2004-04-22 |
PL375447A1 (en) | 2005-11-28 |
US7304071B2 (en) | 2007-12-04 |
AU2003262642A1 (en) | 2004-03-03 |
NZ538715A (en) | 2007-07-27 |
JP4741948B2 (ja) | 2011-08-10 |
KR20050042478A (ko) | 2005-05-09 |
NO20051207L (no) | 2005-05-18 |
WO2004016597A2 (en) | 2004-02-26 |
AU2003262642B2 (en) | 2010-06-17 |
MXPA05001804A (es) | 2005-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313397A (pt) | Inibidores de proteina cinase e usos destes | |
BRPI0512703A (pt) | composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para o tratamento de uma condição ou doença inflamatória ou imune em um indivìduo e para a modulação da função cxcr3 | |
ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
BRPI0414533A (pt) | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 | |
TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
WO2005068468A3 (en) | Heterocyclic protein kinase inhibitors and uses thereof | |
BR0317525A (pt) | Compostos pirazol acìclico, composição terapêutica e farmacêutica, kit, bem como respectivos usos | |
BR0215622A (pt) | Inibidores da dpiv com base em glutaminila | |
BR9908869A (pt) | Composição para evitar ou tratar distúrbios da pele | |
WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
ATE385238T1 (de) | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände | |
MX9606546A (es) | Compuestos inhibidores de la enzima conversiva de interleukina-1 beta. | |
ATE444960T1 (de) | Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer | |
EA200400162A1 (ru) | N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения | |
ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
BRPI0410235A (pt) | inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento | |
BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
BR0212611A (pt) | Compostos de pirazolila substituìdos para o tratamento da inflamação | |
BR0314514A (pt) | Formulações farmacêuticas de modafinil | |
BRPI0409921A (pt) | derivados de éster e amida de ácido 2-cianopropanóico e métodos de seu uso | |
DE60219655D1 (de) | Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung | |
BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
PT923581E (pt) | Beta-carbolina 4-substituidas como imunomoduladores. | |
BRPI0413180A (pt) | gorduras de baixo teor de ácido trans-groxo e composições de gorduras, e métodos de fazer as mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |